Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04954599 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 2026 to Feb 2027v9 Show 5 more changesShow less
    • Start date: Apr 25, 2023 to May 30, 2023
    • Study sites: 3 to 5
    • Study completion date: May 2026 to May 2027
    • Eligibility criteria revised
    • Collaborators: 3 to 5
  2. Lead sponsor: Maastricht University to Maastricht University Medical Centerv8
  3. 2 versions Re-verified since Sep 8, 2023, no change to tracked fieldsv6-v7
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Apr 1, 2023 to Apr 25, 2023
    v5
  5. Start date: Oct 1, 2022 to Apr 1, 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Jun 1, 2022 to Oct 1, 2022
    • Primary completion date: Sep 2025 to Feb 2026
    • Study completion date: Oct 2025 to May 2026
    v3
  2. Primary completion date: Sep 2024 to Sep 2025v2 Show 6 more changesShow less
    • Start date: Oct 2021 to Jun 1, 2022
    • Study completion date: Oct 2024 to Oct 2025
    • Eligibility criteria shortened, about 67 words
    • Study description shortened, about 16 words
    • Collaborators: 4 to 3
    • Publications: 3 to 5
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Maastricht University Medical Center
119 trials monitored
See 5 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Head & Neck Cancer
2,605 trials monitored
See 150 trials at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
and 3 more diseases
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumours or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumour and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIa clinical trial
Trial Details
NCT Number NCT04954599
Lead Sponsor Maastricht University Medical Center
Collaborators: Erasmus Medical Center, Jules Bordet Institute, Academisch Ziekenhuis Maastricht, Vall d'Hebron Institute of Oncology, University Ghent
Conditions
(from sponsor)		 Unspecified Adult Solid Tumor, Protocol Specific
Related terms Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms
Enrollment 126 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov